A Phase 1/2 Study of CBL0137 to Treat Advanced Solid Tumors in Children and Young Adults


Full Title

A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma (PEPN2111) (CIRB)


Researchers in this study are seeking the best dose of CBL0137 in people with solid tumors. They also want to see how well it works against certain cancers.

The best dose was already found in the first part of this study. The people in this study will now be limited to children and young adults with osteosarcoma or certain types of brain or brain stem tumors (gliomas). In addition, their cancers came back or keep growing even with treatment.

CBL0137 blocks signals between molecules inside a cell. Blocking these signals may kill cancer cells. CBL0137 is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You or your child must:

  • Have osteosarcoma or a brain or brain stem glioma that keeps growing even with treatment.
  • Have recovered from the serious side effects of prior therapies before getting CBL0137.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be between the ages of 1 and 30 years.


For more information or to see if you or your child can join this study, please call 833-MSK-KIDS.




Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory



Tara O'Donohue

ClinicalTrials.gov ID